Evidence map›Paper›PMID 35005029›Full record

ArticleJournal of diabetes research2021

Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study.

Annunziata Nusca, Federico Bernardini, Fabio Mangiacapra, Ernesto Maddaloni, Rosetta Melfi, Elisabetta Ricottini, Francesco Piccirillo, Silvia Manfrini, Gian Paolo Ussia, Francesco Grigioni

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Effects of Ranolazine on Vascular Adrenergic Receptors in Rabbit Aorta.International journal of medical sciences · 2026
    Article
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Annunziata NuscaUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.ORCID https://orcid.org/0000-0002-5616-3197
Federico BernardiniUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Fabio MangiacapraUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Ernesto MaddaloniDepartment of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.
Rosetta MelfiUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Elisabetta RicottiniUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Francesco PiccirilloUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Silvia ManfriniUnit of Endocrinology and Diabetes, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Gian Paolo UssiaUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Francesco GrigioniUnit of Cardiac Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 200, 00128 Rome, Italy.
Università Campus Bio-Medico · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRanolazine is a second-line drug for the management of chronic coronary syndromes (CCS). Glucose-lowering and endothelial effects have also been reported with this agent. However, whether ranolazine may improve short-term glycemic variability (GV), strictly related to the prognosis of patients with type 2 diabetes (T2D), is unknown. Thus, we aimed to explore the effects of adding ranolazine to standard anti-ischemic and glucose-lowering therapy on long- and short-term GV as well as on endothelial function and oxidative stress in patients with T2D and CCS.

methodsPatients starting ranolazine (

resultsA significant decline in Hb1Ac levels was reported after 3-month ranolazine treatment (mean change -0.60%; 2-way ANOVA

conclusionsRanolazine added to standard anti-ischemic and glucose-lowering therapy demonstrated benefit in improving the glycemic status of patients with T2D and CCS. How this improvement contributes to the overall myocardial benefit of ranolazine requires further studies.

Indexed as

Analysis of VarianceDiabetes MellitusEndothelial CellsFemaleGlycemic ControlHeart DiseasesHumansMaleMiddle AgedProspective StudiesRanolazineSodium Channel BlockersStatistics, NonparametricRanolazineSodium Channel Blockers

Identifiers

PMID35005029
PMCPMC8741377
OpenAlexW4206046995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.